Pregled bibliografske jedinice broj: 177563
Development of an organic arsenic derivative as a therapy for leukaemia
Development of an organic arsenic derivative as a therapy for leukaemia // Liječnički vjesnik / Čikeš, Nada (ur.).
Zagreb: Hrvatski liječnički zbor, 2003. (pozvano predavanje, domaća recenzija, neobjavljeni rad, znanstveni)
CROSBI ID: 177563 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Development of an organic arsenic derivative as a therapy for leukaemia
Autori
Verstovšek, Srđan ; Golemović, Mirna ; Oršolić, Nada ; Freireich, EJ ; Kantarjian, H
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, neobjavljeni rad, znanstveni
Izvornik
Liječnički vjesnik
/ Čikeš, Nada - Zagreb : Hrvatski liječnički zbor, 2003
Skup
3.hrvatski kongres hematologa I transfuziologa
Mjesto i datum
Opatija, Hrvatska, 23.10.2003. - 26.10.2003
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
arsenic trioxide; organic arsenic derivatives; toxicity
Sažetak
Use of arsenic trioxide (ATO) in other malignancies than APL is limited by its' toxicity. In contrast, organic arsenic derivatives (OAD) are much less toxic ; hepatic methylation of inorganic arsenic to yield OAD is mechanism of detoxification. We have confirmed potent activity of SGLU1 (new OAD) against human leukemia, lymphoma, multiple myeloma cell lines and leukemic cells from leukemia patients, with activity comparable to that of ATO. Mechanism of action of <SGLU1 and ATO differs significantly. SGLU1 is significantly less toxic to healthy donor cells than ATO. This work has high potential for identification of a new therapeutic approach for patients with leukemia.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
